Healthcare trust RTW Biotech Opportunities (RTW) outperformed its major biotech benchmarks in April. The fund delivered a 7% month-on-month increase in net asset value (NAV) per share to $2.59. That return beat the 0.4% gain from the Nasdaq Biotech Index. It also exceeded the 3.7% return generated by the Russell 2000 Biotech Index. The FTSE 250-listed … Continue reading RTW Bio beats key benchmarks again